Tesamorelin Recommended for body recomposition Pros Has been shown to selectively reduce abdominal fat in patients with HIV Can also increase muscle area and strength Promising implications for cognitive and cardiovascular health No reported risk of immunogenicity Cons Studies so far have focused on patients with HIV May cause flu-like symptoms Usually administered by subcutaneous injection Prohibited by the World Anti-Doping Agency Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy excess abdominal lipid accumulation as a result of antiretroviral therapy its efficacy against which was evidenced in a 2010 clinical trial that demonstrated an 18% decrease in visceral fat in intervention subjects compared to placebo.11 Concerning muscle growth, a later study of HIV patients determined that tesamorelin was effective in increasing skeletal muscle area and density.28 Also, because visceral fat is associated with increased cardiovascular mortality, tesamorelin exhibits promise as a treatment for serious health conditions like heart disease and stroke.37 Although tesamorelin studies so far have understandably centered on patients with HIV, theory holds that the peptide should have the same effects on other users

Our team is dedicated to providing exceptional customer service and ensuring that our customers have access to the compounds they need to conduct groundbreaking research
Retatrutide tie in for multi pathway endocrine signaling maps Retatrutide is often included in laboratory signaling programs that explore peptide responsive receptor families beyond the amylin receptor system, enabling multi pathway study designs with shared controls and matched documentation
Bpc-157 enhances this cell migration process, essentially speeding up the recruitment of healing resources to damaged areas
Call (800) 504-5360
The before and after result is real, but the timeline is specific to the tissue type and the severity of the condition being treated